ArticleGastroenterology research and practice2021
Adjunctive Hyperbaric Oxygen Therapy in Refractory Crohn's Disease: An Observational Study.
Article in Gastroenterology research and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Hyperbaric Oxygen Therapy in Surgical Wound Healing and Tissue Salvage: A Structured Narrative Review.Cureus · 2026Review
- Hyperbaric Oxygen Therapy in the Management of Refractory Perianal Crohn's Disease.Journal of clinical medicine · 2025Article
- Hyperbaric Oxygen Therapy in the Treatment of Crohn's Disease.Healthcare (Basel, Switzerland) · 2025Article
- Pyoderma Gangrenosum and Inflammatory Bowel Disease: Recent Insights into Epidemiology, Pathogenesis, and Therapeutic Approaches.Journal of inflammation research · 2025Review
- Use of vedolizumab combined with hyperbaric oxygen therapy to treat enteric fistula in Crohn's disease.Medical gas research · 2024Article
- Perianal disease in inflammatory bowel disease: Broadening treatment and surveillance strategies for anal cancer.World journal of gastroenterology · 2024Review
- Article
- Review
- The new insights of hyperbaric oxygen therapy: focus on inflammatory bowel disease.Precision clinical medicine · 2024Review
- Optimal Management of Refractory Crohn's Disease: Current Landscape and Future Direction.Clinical and experimental gastroenterology · 2024Review
- Managing complex perianal disease after anti-TNF failure: Where to go next?Current research in pharmacology and drug discovery · 2022Review
- A Review of Hyperbaric Oxygen Therapy for Inflammatory Bowel Disease.International journal of general medicine · 2021Review
- The Crucial Role of Nurses in the Comprehensive Management of Postoperative Enteroatmospheric Fistula: A Narrative Review.Current health sciences journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsPatients may experience complications of Crohn's disease (CD) even when treated with optimal medical therapy strategies. Previous data have shown the efficacy of hyperbaric oxygen therapy (HBOT) in the management of complicated CD. However, there is no consensus regarding the optimal number of sessions or duration of treatment regimens. The aim of the present study was to investigate the efficacy of HBOT in CD patients who were refractory to conventional medical management.
methodsThis study included patients who underwent HBOT for the treatment of the following complications: perianal fistulizing Crohn's disease (pCD), enterocutaneous fistulas (ECF), or pyoderma gangrenosum (PG). Complete healing was defined as the closure of external orifice and the absence of active draining (in pCD), complete wound healing (in PG), and granulation or complete wound epithelialization with no enteric draining (in ECF). The persistence of draining and the absence of wound granulation were defined as incomplete healing.
resultsForty patients were included. The mean CD duration was 10.6 ± 5.8 years. pCD comprised most of the included patients (25/62.5%), followed by ECF (
conclusionsAdjunctive HBO was associated with significant healing rates for CD-associated complications such as pCD, ECF, and PG.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.